BioMedNewsBreaks

WednesdayJun 30, 2021 11:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab tests to test centers in Berlin. Delivery is scheduled to begin this week, followed by a brief trial period to integrate and evaluate XPhyto’s new PCR test system with commercial operations expected to commence upon delivery…

Continue Reading

WednesdayJun 30, 2021 10:12 am

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a corporate update, noting that its PALISADE-1 phase 3 trial designed to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (“SAD”) is under way. The announcement also noted that the company is preparing to initiate several exploratory phase 2A clinical trials of…

Continue Reading

TuesdayJun 29, 2021 11:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). An anthracycline, Berubicin falls in a class of anticancer agents that are among the most powerful chemotherapy drugs, proven to be effective against more types of cancer than any other category of chemotherapeutic agents. Fast…

Continue Reading

MondayJun 28, 2021 3:37 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia. WPD, a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme (“GBM”). According to the update, WPD plans to commence its Phase Ib/II Study of Berubicin in the treatment of glioblastoma in the second half of 2021. In addition, CNS Pharmaceuticals has announced open enrollment in the…

Continue Reading

MondayJun 28, 2021 3:14 pm

BioMedNewsBreaks – InvestorBrandNetwork Heightening Visibility, Widening Reach of Roth Capital Partners’ Healthcare Private Company Forum

InvestorBrandNetwork (“IBN”), an innovative corporate communications firm and content distributor, today announced that it is continuing its collaboration with Roth Capital Partners (“Roth”) for its Virtual Healthcare Private Company Forum. The event is shining the spotlight on a diverse selection of companies across biotechnology, pharmaceuticals and medical technologies verticals and featuring engaging discussion panels designed to offer novel insights into some of the latest developments within the healthcare space. The panels will cover a number of topics, including “Novel Approaches to Tumor Eradication,” “Natural Killer Cell Approaches to Eradicate Tumors,” and the “Next Wave of Psychedelic Drug Developers.” IBN, operating in the capacity of…

Continue Reading

FridayJun 25, 2021 11:10 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss 2021 FY Results, Provide Business Update

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, June 29, 2021. VistaGen CEO Shawn Singh and other members of the company’s management team will host the call and provide an update…

Continue Reading

ThursdayJun 24, 2021 10:16 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled to begin at 11:50 a.m. ET. In addition, McKee will contribute to a panel discussion on the future of research and development activities for psychedelic drug compounds. To view the full press release, visit https://ibn.fm/g2YIn…

Continue Reading

WednesdayJun 23, 2021 2:56 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Focused on Greater Supplement Effectiveness

Healthy Extracts (OTCQB: HYEX) develops, sells and distributes proprietary products with proven health benefits through its portfolio of wholly owned subsidiaries that currently comprises Ultimate Brain Nutrients(TM) (“UBN”) and BergametNA(TM). UBN creates formulations that improve brain health while BergametNA develops powerfully proven supplements sourced from the Citrus Bergamot Superfruit(TM) (“bergamot”) and which target cardiovascular and immune health. “Bergamot has a host of health benefits as it is a source of high concentrations of polyphenolic flavanones, measured in terms of the bergamot polyphenolic fraction (‘BPF’),” reads a recent article. Dr. Gerald Haase, MD, a clinical professor of surgery at the University…

Continue Reading

WednesdayJun 23, 2021 2:14 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA,” reads a recent article. “The additional testing and specification development focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can…

Continue Reading

TuesdayJun 22, 2021 1:39 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult glioblastoma multiforme (“GBM”) in the second quarter. Additionally, its sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients and is also…

Continue Reading